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Introduction {#add13748-sec-0005}
============

The core strategies in reducing smoking prevalence are to prevent people from starting smoking, to reduce the number of smokers and to decrease the chances of relapse. This can be achieved by implementing population‐based tobacco control policies (e.g. legislations and mass media campaigns) and smoking cessation programmes (e.g. drug or behavioural therapies) targeted at current smokers. However, due to the increasing number of interventions now available, decision‐makers face difficulties in deciding which intervention to implement. Given scarce resources, relative costs and benefits of those interventions are one of the key decision‐making criteria, thus making the importance of economic evaluations rise in recent years [1](#add13748-bib-0001){ref-type="ref"}, [2](#add13748-bib-0002){ref-type="ref"}.

Economic evaluations combine the outcomes of interventions with their costs, in order to determine which intervention provides the best value for money [3](#add13748-bib-0003){ref-type="ref"}. Such evaluations, for example, have shown that treatment with varenicline [4](#add13748-bib-0004){ref-type="ref"}, [5](#add13748-bib-0005){ref-type="ref"} or behavioural support by mobile phone [6](#add13748-bib-0006){ref-type="ref"} can be cost‐effective. Model‐based economic evaluations are especially appropriate to extrapolate the benefits beyond clinical trials and when a single primary source of data is not sufficient [7](#add13748-bib-0007){ref-type="ref"}. In addition, a model‐based economic evaluation has the ability to adapt itself to a new context, making the process of executing economic evaluations less time‐consuming and thus less costly [8](#add13748-bib-0008){ref-type="ref"}, [9](#add13748-bib-0009){ref-type="ref"}. Unfortunately, such evaluations often originate in affluent societies. The number of lives that can be saved from the use of such evidence elsewhere (e.g. countries in Central and Eastern Europe) is potentially enormous. Sadly, those countries often have too limited research resources to study cost‐effectiveness of such interventions in their own context, highlighting the importance of transferability assessments [9](#add13748-bib-0009){ref-type="ref"}, [10](#add13748-bib-0010){ref-type="ref"}.

The notion of transferability of evidence from one context to others varies widely in the literature. 'Transferability', 'generalizability' and 'external validity' are the concepts used to assess the ability of a study to be relevant to the decision maker\'s context to the extent the findings could actually be used [11](#add13748-bib-0011){ref-type="ref"}, [12](#add13748-bib-0012){ref-type="ref"}, [13](#add13748-bib-0013){ref-type="ref"}, [14](#add13748-bib-0014){ref-type="ref"}, [15](#add13748-bib-0015){ref-type="ref"}. However, a distinction also exists between what is feasible/applicable and what is generalizable/transferable. Applicability refers to 'how can I replicate the intervention in my own decision context?' (the process question) and generalizability refers to 'whether the effectiveness will be similar to that in the original context?' (the outcome question) [12](#add13748-bib-0012){ref-type="ref"}, [13](#add13748-bib-0013){ref-type="ref"}, [15](#add13748-bib-0015){ref-type="ref"}, [16](#add13748-bib-0016){ref-type="ref"}. Therefore, these two underlying questions seem to have defined transferability in the literature.

Transferability assessments to date have focused mainly on the way in which a model is constructed and populated, as modelling provides a well‐defined structure helping us to recognize the limitations and their implications for generalizability of the results [7](#add13748-bib-0007){ref-type="ref"}, [17](#add13748-bib-0017){ref-type="ref"}, [18](#add13748-bib-0018){ref-type="ref"}, [19](#add13748-bib-0019){ref-type="ref"}. There has not been a systematic enquiry in to the transferability of economic evaluations in smoking cessation, although a few systematic reviews in this area exist [20](#add13748-bib-0020){ref-type="ref"}, [21](#add13748-bib-0021){ref-type="ref"}. The review by Kirsch *et al*. [21](#add13748-bib-0021){ref-type="ref"}, for instance, limits itself to a narrow definition of study population and to a specific type of economic model. In this paper, we therefore set out to: (i) identify different types of models used in economic evaluations of smoking cessation; (ii) analyse the quality of the included models examining their attributes; and (iii) ascertain their transferability to a new context.

Methods {#add13748-sec-0006}
=======

Search strategy and implementation {#add13748-sec-0007}
----------------------------------

A systematic search was conducted to identify all relevant models used for economic evaluation in smoking cessation on the following databases: National Health Service (NHS) Economic Evaluation Database (NHS EED), Health Technology Assessment (HTA), Medline and EMBASE. They were searched for publications in English language between 1996 and April 2015. The search strategy was based on related published systematic reviews [20](#add13748-bib-0020){ref-type="ref"}, [22](#add13748-bib-0022){ref-type="ref"}, [23](#add13748-bib-0023){ref-type="ref"}, [24](#add13748-bib-0024){ref-type="ref"}, leading to the final search terms 'smoking', 'nicotine' and 'tobacco' in NHS EED and HTA. Medline and EMBASE required additional terms related to model‐based economic evaluation, which were based on Wilczynski *et al*. [25](#add13748-bib-0025){ref-type="ref"} and McKinlay [26](#add13748-bib-0026){ref-type="ref"} to acquire high sensitivity as well as high specificity [27](#add13748-bib-0027){ref-type="ref"}. Supporting information, [Table S1](#add13748-supitem-0001){ref-type="supplementary-material"} shows an overview of the search strategies used by databases. All results were exported to EndNote (Thomson Reuters) version X7, where duplications were removed automatically and remaining duplicates checked manually.

Exclusion criteria and screening {#add13748-sec-0008}
--------------------------------

Title and abstract screening for the first 50 papers was performed independently by two reviewers (M.H. and M.B.) based on the following exclusion criteria: (1) topic not in smoking cessation (as the focus was on the interventions to reduce tobacco use), (2) no original research (to avoid inclusion of review of evidence or opinion pieces), (3) no model‐based economic evaluation (to avoid inclusion of other designs, e.g. trial‐based evaluations), (4) no adult general population (to focus on adults, rather than children), (5) no high‐income country (to reduce study heterogeneity by including comparable, industrialized countries based on their income levels) and (6) not available in the English language (practicality reasons mainly to address resource constraints). No differences in exclusion/inclusion were observed between both reviewers; only minor discrepancies were recorded in the reason of exclusion. The inter‐rater reliability (IRR) gave a Cohen\'s kappa of 0.912, meaning almost perfect agreement [28](#add13748-bib-0028){ref-type="ref"}. Remaining discrepancies were discussed, leading to full agreement. Screening of the remaining papers was then completed by one researcher (M.B.). Full text screening was performed independently by two reviewers (M.B. and K.L.C. or M.H.). There were only minor discrepancies between the reviewers, which led to full agreement after discussion. Supporting information, [Tables S2 and S3](#add13748-supitem-0001){ref-type="supplementary-material"} show an extended list of exclusion criteria for full‐text screening.

Data extraction {#add13748-sec-0009}
---------------

Data on the following items were extracted using an Excel template adapted from published studies [20](#add13748-bib-0020){ref-type="ref"}, [29](#add13748-bib-0029){ref-type="ref"}, [30](#add13748-bib-0030){ref-type="ref"} and included: study attributes (type of evaluation, interventions, comparator and country); model (type, transition or health states, time horizon and perspective); effectiveness (outcome and discount rate, primary measure of effectiveness and utility valuations); costs (perspective, categories, resource, index year and discount rate); uncertainty (type and outcome of sensitivity analysis); and results and major limitations.

As data from some included studies were already extracted by the University of York\'s Centre for Reviews and Dissemination (CRD) (*n* = 39 of 64), only one researcher (M.B.) extracted data independently on those studies and compared with the CRD extraction. The CRD database contains clear and structured summaries of the economic analyses by experts, and therefore it was deemed sufficient to compare the results of data extraction to these summaries. For the remaining studies that were not included in the CRD database, the data were extracted independently by two reviewers (M.B. and one of the following: M.H., K.L.C., R.D.K. and P.K). Any disagreement between the reviewers was resolved by consensus with a third reviewer.

Quality appraisal {#add13748-sec-0010}
-----------------

In order to appraise the quality, 10% of the included studies were first assessed independently by M.B. and M.H., using a quality checklist and corresponding classification from the National Institute for Health and Care Excellence (NICE) Methodology Guide with the aim to filter out quality‐poor studies [31](#add13748-bib-0031){ref-type="ref"}. The quality checklist was based on three major criteria: (1) the study was conducted from a relevant perspective (i.e. at least payer or health‐care perspective; (2) the study was a cost--utility or cost--benefit analysis with cost/quality adjusted life years (QALY) or benefit--cost ratio reported; and (3) limitations, either stated in the original study or identified by the reviewers during data extraction stage. Once the overall assessment using these criteria was completed, the studies were assigned to one of the following three classifications: (i) a study with minor limitations (ML); (ii) a study with potentially serious limitations (PSL); or (iii) a study with very serious limitations (VSL). As full agreement on quality classification was reached in the 10% of the included studies, M.B. then completed the quality appraisal of the remaining studies.

Transferability assessment {#add13748-sec-0011}
--------------------------

The studies appraised as the one with minor limitations (ML) were considered to be of sufficient quality to be included for transferability assessment applying the EURONHEED checklist [9](#add13748-bib-0009){ref-type="ref"}. Two independent researchers (M.B. and one of the following: M.H., K.L.C., R.D.K. and P.K.) applied the checklist. The EURONHEED checklist was developed originally by Boulenger *et al*. [9](#add13748-bib-0009){ref-type="ref"} and described and updated further with guidelines by Nixon *et al*. [32](#add13748-bib-0032){ref-type="ref"}. It consists of 42 questions, 26 of which relate to overall methodological quality and internal validity, and 16 questions relate to transferability. An overview of all questions is provided in Supporting information, [Table S4](#add13748-supitem-0001){ref-type="supplementary-material"}. Every question can be answered by 'yes/partially/no or not applicable (NA)', assigning a score of 1, 0.5 and 0, respectively. While each item in the checklist is treated equally (but implicitly giving more weight to 16 of the 42 items), the assigned score to each question thus additionally provides another weight to reflect the extent to which each item was reported in the study being assessed [32](#add13748-bib-0032){ref-type="ref"}. The combination of the questions generates an overall summary score [9](#add13748-bib-0009){ref-type="ref"}, [10](#add13748-bib-0010){ref-type="ref"}. We calculated two summary scores: the total summary score including all 42 items and the transferability score including the 16 items. The summary scores were calculated using the following formula; $\frac{1}{n - x}\sum_{i}\mathit{Si} \times 100$ *,* in which *n* is the number of questions, *x* is the number of questions for which the response was NA and *S* is the score of each question [9](#add13748-bib-0009){ref-type="ref"}. The summary scores reflect how thoroughly key methodological items are reported as the quality of reporting is paramount for generalizability/transferability [32](#add13748-bib-0032){ref-type="ref"}. In addition to this, we calculated the scored percentage of the total score possible per section. This showed us what sections within model‐based economic evaluations were of sufficient quality and which needed further improvement. For example, a score of 0.75 means that 75% of this section is of sufficient quality.

Results {#add13748-sec-0012}
=======

Search outcomes {#add13748-sec-0013}
---------------

The systematic literature search yielded 1925 references. After removing duplicates, 1500 studies were included for title and abstract screening which led to a total of 101 studies selected for full text screening. On applying the exclusion criteria, 64 studies were judged to be eligible for data extraction. Thirteen of the 64 studies were included for transferability assessment. An overview of the process is provided in Fig. [1](#add13748-fig-0001){ref-type="fig"}.

![Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) flow diagram, based on National Health Service Economic Evaluation Database (NHS EED) and Health Technology Assessment Database (HTA). \[Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](ADD-112-946-g001){#add13748-fig-0001}

Overview of studies {#add13748-sec-0014}
-------------------

An overview of the identified models is shown in Table [1](#add13748-tbl-0001){ref-type="table-wrap"}. Most studies originated from Europe (*n* = 30 of 64) and the United States (*n* = 24 of 64), followed by Australia (*n* = four of 64) and Asia (*n* = two of 64). Three of 64 studies were multi‐continental.

###### 

Overview of studies by population, intervention, comparators and outcome.

  Author, year         Country                                                     Population                                                                                                        Intervention                                                                                                                                                          Comparator                                                        Outcome
  -------------------- ----------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- -----------------------------------------
  Ahmad, 2005a         CA, USA                                                     General Californian population                                                                                    Raising legal smoking age from 18 to 21                                                                                                                               Legal smoking age 18, 19, 20                                      QALY
  Ahmad, 2005b         USA                                                         General American population                                                                                       Raising legal smoking age from 18 to 21                                                                                                                               No intervention                                                   LY gained and QALY
  Annemans, 2015       Belgium                                                     18+ Belgian smokers                                                                                               Varenicline in retreatment                                                                                                                                            No treatment, and retreatment with bupropion or NRT               QALY
  Annemans, 2009       Belgium                                                     18+ Belgian smokers                                                                                               Varenicline                                                                                                                                                           Pharmacotherapies, brief counselling and unaided cessation        LY gained and QALY
  Athanasakis, 2012    Greece                                                      18+ Greek smokers                                                                                                 Varenicline                                                                                                                                                           Bupropion, NRT and unaided cessation                              QALY
  Bae, 2009            South Korea                                                 General Korean population                                                                                         Varenicline                                                                                                                                                           NRT, bupropion and no drugs                                       QALY
  Bauld, 2011          Scotland                                                    Not reported                                                                                                      One‐to‐one counselling or group‐based support programme                                                                                                               No intervention                                                   QALY
  Bertram, 2007        Australia                                                   Australian smokers aged 20--79                                                                                    NRT or bupropion                                                                                                                                                      No intervention                                                   DALY
  Bolin, 2006          Sweden                                                      Swedish smokers aged 35+                                                                                          Bupropion tablets with four nurse visits for motivational support                                                                                                     NRT                                                               QALY
  Bolin, 2008          Sweden                                                      Swedish smokers aged 18+                                                                                          Varenicline                                                                                                                                                           Bupropion                                                         QALY
  Bolin, 2009a         Sweden                                                      Swedish adult population                                                                                          12‐week varenicline treatment expanded with 12 weeks of maintenance with varenicline                                                                                  12 weeks of varenicline +12 weeks of placebo                      QALY
  Bolin, 2009b         Belgium, France, Sweden                                     Not reported                                                                                                      Varenicline                                                                                                                                                           NRT                                                               QALY
  Boyd, 2009           UK                                                          Glasgow smoking population                                                                                        'Starting fresh' and 'Smoking concerns'                                                                                                                               Self‐quit                                                         QALY
  Brown, 2014          England                                                     16+ without having quit successfully in the last month                                                            Stoptober                                                                                                                                                             Usual situation for all other months                              LY gained and QALY
  Cantor, 2015         USA, Texas                                                  Physicians and pharmacists from 16 communities in Texas Participants: 18+                                         The health‐care team approach to smoking cessation: ETOEP                                                                                                             Usual practice                                                    QALY
  Chevreul, 2014       France                                                      Insured current French smokers aged 15--75 years                                                                  Full coverage of the medical management of smoking cessation                                                                                                          Current situation                                                 ICER per LY gained
  Cornuz, 2006         Canada, France, Spain, Switzerland, UK, USA                 Smokers smoking \> 20 cigarettes per day                                                                          Four NRTs (gum, patch, spray, inhaler) and bupropion, given as adjunct to cessation counselling                                                                       Not Reported                                                      LY gained
  Cornuz, 2003         A European country (some data used from Switzerland)        Smokers smoking \> 20 cigarettes per day                                                                          Four NRTs (gum, patch, spray, inhaler) and bupropion, given as adjunct to cessation counselling                                                                       GP counselling during routine visit                               Incremental cost per LY gained
  Croghan, 1997        USA, Rochester                                              Smokers aged 18+                                                                                                  Non‐physician smoking cessation counselling                                                                                                                           No intervention                                                   LY gained
  Dino, 2008           USA                                                         Adolescents aged 17--25 years                                                                                     American Lung Association\'s Not On Tobacco national teen smoking cessation programme                                                                                 Brief intervention                                                Discounted LY
  Feenstra, 2005       The Netherlands                                             Dynamic population                                                                                                Face‐to‐face smoking cessation interventions                                                                                                                          Current situation                                                 LY gained and QALY
  Fiscella, 1996       USA                                                         Not reported                                                                                                      Nicotine patches as an adjunct to physician‐based counselling                                                                                                         Physician‐based counselling                                       QALY
  Guerriero, 2013      UK                                                          Smokers aged 16+                                                                                                  Text‐based support in adjunct to current practice                                                                                                                     Current situation                                                 LY gained and QALY
  Halpern, 2007a       USA                                                         Not reported                                                                                                      Varenicline                                                                                                                                                           Nicotine patch, bupropion, and no pharmacotherapy                 ROI, IRR, B--C‐ratio
  Halpern, 2007b       USA                                                         Reflection of US population                                                                                       Work‐place smoking cessation coverage                                                                                                                                 No coverage                                                       IRR, ROI
  Heitjan, 2008        USA                                                         American whites                                                                                                   Nicotine patch, bupropion, varenicline and tailored therapy based on genetic testing                                                                                  No intervention                                                   Residual LY
  Hill, 2006           USA                                                         Not reported                                                                                                      NRT (gum, patch, inhaler, nasal spray), Zyban or combinations                                                                                                         No intervention                                                   ICER
  Hojgaard, 2011       Denmark                                                     General Danish population                                                                                         Smoking cessation programme and a smoking ban                                                                                                                         Current situation                                                 LY gained
  Hoogendoorn, 2008    The Netherlands                                             General Dutch population                                                                                          Varenicline                                                                                                                                                           No intervention, bupropion, nortriptyline or NRT                  Number of quitters, LY gained, and QALY
  Howard, 2008         USA                                                         US adult 18+ population                                                                                           Varenicline                                                                                                                                                           Bupropion, NRT, and unaided quitting                              QALY
  Hurley, 2008         Australia                                                   General Australian population                                                                                     Australian National Tobacco Campaign                                                                                                                                  Current situation                                                 LY gained and QALY
  Igarashi, 2009       Japan                                                       Japanese smokers aged 20+ smoking \>20 cigarettes per day                                                         Varenicline combined with counselling                                                                                                                                 Counselling                                                       QALY
  Jackson, 2007        USA                                                         Not reported                                                                                                      Varenicline                                                                                                                                                           Bupropion                                                         Net benefit
  Knight, 2010         USA                                                         General American population making single quit attempt                                                            Varenicline 12 + 12 weeks                                                                                                                                             Bupropion, NRT and unaided cessation                              QALY
  Lai, 2007            Estonia                                                     Estonian smokers aged 15--59                                                                                      Increase of tax, clean indoor air law enforcement, and NRT                                                                                                            No intervention (do‐nothing counterfactual)                       DALY
  Lal, 2014            Australia                                                   Smokers aged 35--100                                                                                              Telephone counselling                                                                                                                                                 Self‐help                                                         DALY
  Levy, 2006           USA                                                         Employees aged 18--64                                                                                             Four coverage scenarios                                                                                                                                               No coverage                                                       Changes in medical expenditures
  Levy, 2002           USA                                                         Hypothetical cohort of smokers                                                                                    Coverage of costs of different combinations of treatment, and brief interventions by care providers                                                                   No intervention                                                   Quit rates
  Linden, 2010         Finland                                                     Finnish adult smokers making a first quit attempt                                                                 Varenicline                                                                                                                                                           Prescribed medicine, bupropion or unaided cessation               LY gained and QALY
  McGhan, 1996         Not reported                                                Not reported                                                                                                      Self‐care, behavioural therapy, group withdrawal clinic or nicotine patch                                                                                             Not reported                                                      Net benefit
  Nielsen, 2000        USA                                                         Smokers enrolled on a smoking cessation programme                                                                 Nicotine patch, bupropion, or combination                                                                                                                             Placebo                                                           Net benefit
  Nohlert, 2013        Sweden                                                      General Swedish population                                                                                        Low and high intensity smoking cessation program                                                                                                                      No intervention                                                   QALY
  O\'Donnell, 2011     USA                                                         Dynamic population                                                                                                Cold turkey, behavioural therapy, medication therapy or combinations                                                                                                  No intervention                                                   LY gained
  Olsen, 2006          Denmark                                                     General Danish population                                                                                         Group courses, individual courses or quick interventions                                                                                                              No intervention                                                   LY gained
  Ong, 2005            USA, Minnesota                                              Minnesota population of smokers                                                                                   Free NRT                                                                                                                                                              State‐wide campaign of smoke‐free work‐places                     QALY
  Over, 2014           The Netherlands                                             Dutch smokers aged 25--80                                                                                         Tax increase or reimbursement                                                                                                                                         Current situation                                                 QALY
  Pinget, 2007         Switzerland                                                 Swiss smokers                                                                                                     Physician training in smoking cessation counselling                                                                                                                   Physician training in dyslipidaemia management                    LY gained
  Ranson, 2002         139 countries                                               Current smokers in 1995                                                                                           Tobacco control policies (price increases, NRT, non‐price interventions)                                                                                              No tobacco control policy                                         DALY saved
  Shearer, 2006        Australia                                                   General Australian population                                                                                     Brief advice, telephone counselling, NRT or bupropion                                                                                                                 No intervention, brief advice, counselling or pharmacotherapies   ICER
  Simpson, 2013        USA                                                         New York State aged 18+                                                                                           New York Tobacco Control Programme                                                                                                                                    No intervention                                                   Smoking costs avoided
  Song, 2002           UK                                                          Hypothetical cohort of smokers                                                                                    Advice plus NRT, advice plus bupropion or advice plus NRT and bupropion                                                                                               Advice or counselling only                                        LY gained
  Stapleton, 1999      UK                                                          Smokers in general                                                                                                Transdermal nicotine patches with GP counselling                                                                                                                      GP counselling                                                    LY gained
  Stapleton, 2012      Data used from USA and UK                                   Smokers in general                                                                                                Cytisine, Agency for Health Care Policy and Research Guideline for smoking cessation, NICE appraisal of NRT, or effect size given as an odds ratio or relative rate   Placebo                                                           LY gained
  Taylor, 2011         UK                                                          Hypothetical cohort of smokers who recently initiated quit attempts                                               NRT, bupropion or varenicline                                                                                                                                         No drug therapy                                                   QALY
  Tran, 2002           USA, Virginia                                               Smokers aged 21--70 who tried (at least once) to quit smoking                                                     Cold turkey, nicotine patch, nicotine gum or bupropion                                                                                                                Self‐quit                                                         QALY
  Van Baal, 2007       The Netherlands                                             Dynamic population                                                                                                Tobacco tax increase                                                                                                                                                  Current situation                                                 LY gained and QALY
  Van Genugten, 2003   The Netherlands                                             Dutch population                                                                                                  Policy measures ('Don\'t start', 'quit', 'tax')                                                                                                                       Future smoking prevalence is based on trend extrapolation         DALY
  Vemer, 2010a         The Netherlands, Belgium, Germany, Sweden, France, and UK   Smokers aged 18+ in the Netherlands, Belgium, Germany, Sweden, France and the UK                                  NRT, bupropion or varenicline                                                                                                                                         Unaided quit attempt                                              QALY
  Vemer, 2010b         The Netherlands                                             Dutch smokers aged 18+                                                                                            Smoking cessation support                                                                                                                                             Current situation                                                 QALY
  Von Wartburg, 2014   Canada, France, Spain, Switzerland, UK, USA                 Cohort representative of Canadian demographics, smokers who seriously consider quitting within the next 30 days   Standard 12 weeks of varenicline, or 12 + 12 weeks of varenicline                                                                                                     Bupropion, NRT, or unaided cessation                              QALY
  Warner, 1996         USA                                                         Hypothetical cohort of blue‐collar workers                                                                        Work‐site smoking‐cessation programme                                                                                                                                 No intervention                                                   LY gained, medical expenditures saved
  Welton, 2008         UK                                                          Not reported                                                                                                      Genetic testing of DRD2 Taq1ANRT, bupropion, their combination, or standard care                                                                                      Brief advice or individual counselling                            Incremental net benefit
  Xenakis, 2009        USA                                                         Not reported                                                                                                      Varenicline with counselling                                                                                                                                          Counselling + bupropion or placebo                                Incremental costs
  Xu, 2014             USA                                                         US adult 18+ population                                                                                           Anti‐smoking campaign                                                                                                                                                 No campaign                                                       LY gained and QALY

NRT = nicotine replacement therapy; QALY = quality adjusted life years; DALY = disability adjusted life years; NICE = National Institute for Health and Care Excellence; GP general practitioner; ICER = incremental cost‐effectiveness ratio; LY = life years; IRR = inter‐rater reliability; ROI = return on investment; B--C = benefit--cost.

The populations in the analyses were described mainly as the general adult population of smokers. In three studies the populations were described further as smoking 20 cigarettes per day or more [33](#add13748-bib-0033){ref-type="ref"}, [34](#add13748-bib-0034){ref-type="ref"}, [35](#add13748-bib-0035){ref-type="ref"}, making or considering a single or first quit attempt [36](#add13748-bib-0036){ref-type="ref"}, [37](#add13748-bib-0037){ref-type="ref"}, [38](#add13748-bib-0038){ref-type="ref"}, [39](#add13748-bib-0039){ref-type="ref"} or had recently tried to quit smoking [40](#add13748-bib-0040){ref-type="ref"}, [41](#add13748-bib-0041){ref-type="ref"}. In five studies the population was described only as a dynamic and/or hypothetical cohort [42](#add13748-bib-0042){ref-type="ref"}, [43](#add13748-bib-0043){ref-type="ref"}, [44](#add13748-bib-0044){ref-type="ref"}, [45](#add13748-bib-0045){ref-type="ref"}, [46](#add13748-bib-0046){ref-type="ref"} and in nine studies the population was not reported at all [47](#add13748-bib-0047){ref-type="ref"}, [48](#add13748-bib-0048){ref-type="ref"}, [49](#add13748-bib-0049){ref-type="ref"}, [50](#add13748-bib-0050){ref-type="ref"}, [51](#add13748-bib-0051){ref-type="ref"}, [52](#add13748-bib-0052){ref-type="ref"}, [53](#add13748-bib-0053){ref-type="ref"}, [54](#add13748-bib-0054){ref-type="ref"}, [55](#add13748-bib-0055){ref-type="ref"}.

A significant part of the intervention was smoking cessation programmes, either pharmacotherapy [4](#add13748-bib-0004){ref-type="ref"}, [5](#add13748-bib-0005){ref-type="ref"}, [36](#add13748-bib-0036){ref-type="ref"}, [37](#add13748-bib-0037){ref-type="ref"}, [38](#add13748-bib-0038){ref-type="ref"}, [40](#add13748-bib-0040){ref-type="ref"}, [41](#add13748-bib-0041){ref-type="ref"}, [48](#add13748-bib-0048){ref-type="ref"}, [50](#add13748-bib-0050){ref-type="ref"}, [51](#add13748-bib-0051){ref-type="ref"}, [53](#add13748-bib-0053){ref-type="ref"}, [55](#add13748-bib-0055){ref-type="ref"}, [56](#add13748-bib-0056){ref-type="ref"}, [57](#add13748-bib-0057){ref-type="ref"}, [58](#add13748-bib-0058){ref-type="ref"}, [59](#add13748-bib-0059){ref-type="ref"}, [60](#add13748-bib-0060){ref-type="ref"}, [61](#add13748-bib-0061){ref-type="ref"}, [62](#add13748-bib-0062){ref-type="ref"}, [63](#add13748-bib-0063){ref-type="ref"}, [64](#add13748-bib-0064){ref-type="ref"}, [65](#add13748-bib-0065){ref-type="ref"}, behavioural therapy [6](#add13748-bib-0006){ref-type="ref"}, [42](#add13748-bib-0042){ref-type="ref"}, [47](#add13748-bib-0047){ref-type="ref"}, [66](#add13748-bib-0066){ref-type="ref"}, [67](#add13748-bib-0067){ref-type="ref"}, [68](#add13748-bib-0068){ref-type="ref"}, [69](#add13748-bib-0069){ref-type="ref"} or a combination of these [33](#add13748-bib-0033){ref-type="ref"}, [34](#add13748-bib-0034){ref-type="ref"}, [35](#add13748-bib-0035){ref-type="ref"}, [43](#add13748-bib-0043){ref-type="ref"}, [45](#add13748-bib-0045){ref-type="ref"}, [46](#add13748-bib-0046){ref-type="ref"}, [49](#add13748-bib-0049){ref-type="ref"}, [52](#add13748-bib-0052){ref-type="ref"}, [54](#add13748-bib-0054){ref-type="ref"}, [70](#add13748-bib-0070){ref-type="ref"}, [71](#add13748-bib-0071){ref-type="ref"}, [72](#add13748-bib-0072){ref-type="ref"}, [73](#add13748-bib-0073){ref-type="ref"}, [74](#add13748-bib-0074){ref-type="ref"}, [75](#add13748-bib-0075){ref-type="ref"}. Several studies evaluated wider tobacco control interventions [39](#add13748-bib-0039){ref-type="ref"}, [44](#add13748-bib-0044){ref-type="ref"}, [76](#add13748-bib-0076){ref-type="ref"}, [77](#add13748-bib-0077){ref-type="ref"}, [78](#add13748-bib-0078){ref-type="ref"}, [79](#add13748-bib-0079){ref-type="ref"}, [80](#add13748-bib-0080){ref-type="ref"}, [81](#add13748-bib-0081){ref-type="ref"}, [82](#add13748-bib-0082){ref-type="ref"}, [83](#add13748-bib-0083){ref-type="ref"}, [84](#add13748-bib-0084){ref-type="ref"}, [85](#add13748-bib-0085){ref-type="ref"}, [86](#add13748-bib-0086){ref-type="ref"}, [87](#add13748-bib-0087){ref-type="ref"}, [88](#add13748-bib-0088){ref-type="ref"}, whereas five studies included both smoking cessation programmes and tobacco control interventions [89](#add13748-bib-0089){ref-type="ref"}, [90](#add13748-bib-0090){ref-type="ref"}, [91](#add13748-bib-0091){ref-type="ref"}, [92](#add13748-bib-0092){ref-type="ref"}, [93](#add13748-bib-0093){ref-type="ref"}.

In a number of studies, the authors selected 'no intervention' or 'current situation' as comparator**.** All other studies described the comparators in more detail (Table [1](#add13748-tbl-0001){ref-type="table-wrap"}).

The main measure of outcome used is the QALY. In total, 23 of 64 studies reported QALY as their main outcome [5](#add13748-bib-0005){ref-type="ref"}, [35](#add13748-bib-0035){ref-type="ref"}, [38](#add13748-bib-0038){ref-type="ref"}, [40](#add13748-bib-0040){ref-type="ref"}, [41](#add13748-bib-0041){ref-type="ref"}, [47](#add13748-bib-0047){ref-type="ref"}, [48](#add13748-bib-0048){ref-type="ref"}, [49](#add13748-bib-0049){ref-type="ref"}, [56](#add13748-bib-0056){ref-type="ref"}, [58](#add13748-bib-0058){ref-type="ref"}, [59](#add13748-bib-0059){ref-type="ref"}, [61](#add13748-bib-0061){ref-type="ref"}, [62](#add13748-bib-0062){ref-type="ref"}, [63](#add13748-bib-0063){ref-type="ref"}, [65](#add13748-bib-0065){ref-type="ref"}, [69](#add13748-bib-0069){ref-type="ref"}, [70](#add13748-bib-0070){ref-type="ref"}, [76](#add13748-bib-0076){ref-type="ref"}, [78](#add13748-bib-0078){ref-type="ref"}, [81](#add13748-bib-0081){ref-type="ref"}, [86](#add13748-bib-0086){ref-type="ref"}, [88](#add13748-bib-0088){ref-type="ref"}, [94](#add13748-bib-0094){ref-type="ref"}, followed by life years (LY) gained (*n* = nine of 64) [33](#add13748-bib-0033){ref-type="ref"}, [43](#add13748-bib-0043){ref-type="ref"}, [46](#add13748-bib-0046){ref-type="ref"}, [66](#add13748-bib-0066){ref-type="ref"}, [67](#add13748-bib-0067){ref-type="ref"}, [68](#add13748-bib-0068){ref-type="ref"}, [73](#add13748-bib-0073){ref-type="ref"}, [74](#add13748-bib-0074){ref-type="ref"}, [89](#add13748-bib-0089){ref-type="ref"} or a combination of these (*n* = 12 of 64) [4](#add13748-bib-0004){ref-type="ref"}, [6](#add13748-bib-0006){ref-type="ref"}, [35](#add13748-bib-0035){ref-type="ref"}, [36](#add13748-bib-0036){ref-type="ref"}, [37](#add13748-bib-0037){ref-type="ref"}, [39](#add13748-bib-0039){ref-type="ref"}, [42](#add13748-bib-0042){ref-type="ref"}, [44](#add13748-bib-0044){ref-type="ref"}, [57](#add13748-bib-0057){ref-type="ref"}, [77](#add13748-bib-0077){ref-type="ref"}, [80](#add13748-bib-0080){ref-type="ref"}, [83](#add13748-bib-0083){ref-type="ref"}. Five of 64 studies reported disability adjusted life years (DALY) as their main outcome [60](#add13748-bib-0060){ref-type="ref"}, [82](#add13748-bib-0082){ref-type="ref"}, [90](#add13748-bib-0090){ref-type="ref"}, [91](#add13748-bib-0091){ref-type="ref"}, [92](#add13748-bib-0092){ref-type="ref"}, and only four of 64 (incremental) net benefit [52](#add13748-bib-0052){ref-type="ref"}, [53](#add13748-bib-0053){ref-type="ref"}, [55](#add13748-bib-0055){ref-type="ref"}, [71](#add13748-bib-0071){ref-type="ref"}. There were two of 64 studies reporting only the intermediate outcomes of the intervention [85](#add13748-bib-0085){ref-type="ref"}, [93](#add13748-bib-0093){ref-type="ref"} (Table [1](#add13748-tbl-0001){ref-type="table-wrap"}).

Overview of economic models {#add13748-sec-0015}
---------------------------

Table [2](#add13748-tbl-0002){ref-type="table-wrap"} shows the main model attributes used in the included studies. Thirty of 64 studies used a Markov model, 12 of which used a specific type called the benefits of smoking cessation on outcomes (BENESCO) model [4](#add13748-bib-0004){ref-type="ref"}, [5](#add13748-bib-0005){ref-type="ref"}, [36](#add13748-bib-0036){ref-type="ref"}, [37](#add13748-bib-0037){ref-type="ref"}, [48](#add13748-bib-0048){ref-type="ref"}, [56](#add13748-bib-0056){ref-type="ref"}, [57](#add13748-bib-0057){ref-type="ref"}, [58](#add13748-bib-0058){ref-type="ref"}, [59](#add13748-bib-0059){ref-type="ref"}, [61](#add13748-bib-0061){ref-type="ref"}, [62](#add13748-bib-0062){ref-type="ref"}, [65](#add13748-bib-0065){ref-type="ref"}. Decision‐tree models [41](#add13748-bib-0041){ref-type="ref"}, [43](#add13748-bib-0043){ref-type="ref"}, [52](#add13748-bib-0052){ref-type="ref"}, [55](#add13748-bib-0055){ref-type="ref"}, [63](#add13748-bib-0063){ref-type="ref"}, [71](#add13748-bib-0071){ref-type="ref"}, [75](#add13748-bib-0075){ref-type="ref"}, [83](#add13748-bib-0083){ref-type="ref"}, [93](#add13748-bib-0093){ref-type="ref"}, discrete‐event simulations (DES) [45](#add13748-bib-0045){ref-type="ref"}, [54](#add13748-bib-0054){ref-type="ref"}, the chronic disease model (RIVM‐CDM) [44](#add13748-bib-0044){ref-type="ref"}, [81](#add13748-bib-0081){ref-type="ref"}, [88](#add13748-bib-0088){ref-type="ref"}, the tobacco policy model (TPM) [76](#add13748-bib-0076){ref-type="ref"}, [77](#add13748-bib-0077){ref-type="ref"}, the quit benefits model (QBM) [80](#add13748-bib-0080){ref-type="ref"}, the World Health Organization (WHO) model [90](#add13748-bib-0090){ref-type="ref"}, the global health outcomes model (GHO model) [70](#add13748-bib-0070){ref-type="ref"} and the abstinent‐contingent treatment model (ABT model) [73](#add13748-bib-0073){ref-type="ref"} were also used. Twelve of 64 studies did not report explicitly the model used, reporting only decision analysis modelling or simulation modelling [39](#add13748-bib-0039){ref-type="ref"}, [50](#add13748-bib-0050){ref-type="ref"}, [51](#add13748-bib-0051){ref-type="ref"}, [66](#add13748-bib-0066){ref-type="ref"}, [69](#add13748-bib-0069){ref-type="ref"}, [72](#add13748-bib-0072){ref-type="ref"}, [74](#add13748-bib-0074){ref-type="ref"}, [78](#add13748-bib-0078){ref-type="ref"}, [86](#add13748-bib-0086){ref-type="ref"} or limiting the description to only dynamic or static modelling [42](#add13748-bib-0042){ref-type="ref"}, [82](#add13748-bib-0082){ref-type="ref"}, [92](#add13748-bib-0092){ref-type="ref"}.

###### 

Characteristics showed per model and summary of most reported characteristics.

  Type of model                              Study                                  Characteristics                                                                                                                                                                                                                                                                                                                                    
  ------------------------------------------ -------------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------------- -------------------------------------- ---------------- ---------------------------------- ------------------------------------------------------------------------------------------------- ----------------------------------------------------
  Markov (*n* = 30)                          Annemans, 2015                         4                                                                                                               Life‐time                             Health‐care payer                      1.5 and 3%       1.5 and 3%                         Abstinence rates                                                                                  USA and PSA
                                             Annemans, 2009                         4 + 6                                                                                                           Life‐time                             Health‐care payer                      1.5%             3%                                 Continuous abstinence rates                                                                       USA and PSA
                                             Athanasakis, 2012                      5                                                                                                               Life‐time                             Societal                               3%               3%                                 Continuous abstinence rates                                                                       PSA
                                             Bae, 2009                              NR                                                                                                              Life‐time                             NR                                     5%               5%                                 Quit rates                                                                                        USA and PSA
                                             Bertram, 2007                          3                                                                                                               Life‐time                             Health‐care system                     3%               3%                                 Quit rates                                                                                        PSA
                                             Bolin, 2008                            NR                                                                                                              20 and 50 years                       Health‐care and societal               3%               3%                                 Probability of cessation                                                                          DSA and PSA
                                             Bolin, 2009a                           NR                                                                                                              50 years                              NR                                     3%               3%                                 Smoking prevalence and quit rates                                                                 USA, MSA, and PSA
                                             Bolin, 2009b                           SC intervention +4                                                                                              Life‐time                             Health‐care system                     3.5%             3.5%                               Continuous abstinence rates                                                                       PSA, MSA, and DSA
                                             Chevreul, 2014                         3                                                                                                               Life‐time                             Social Health Insurance                3%               3%                                 Quit rates                                                                                        PSA
                                             Cornuz, 2006                           NR                                                                                                              Life‐time                             NR                                     NR               3%                                 Odds ratio for quitting                                                                           USA
                                             Cornuz, 2003                           NR                                                                                                              NR                                    Third‐party payer                      3%               3%                                 Odds ratio for quitting                                                                           NR
                                             Dino, 2008                             Current smoker, quit, reduce, stay smoker                                                                       Life‐time                             School                                 3%               3%                                 Quit rates                                                                                        MSA and ECA
                                             Fiscella, 1996                         NR                                                                                                              NR                                    Health‐care payer                      3%               3%                                 Cessation rates                                                                                   USA and PSA
                                             Guerriero, 2013                        3 + MI, CHD, stroke, lung cancer, COPD                                                                          Life‐time                             Health service (UK NHS)                3.5%             3.5%                               Relative risk of quitting, relapse rates                                                          DSA and PSA
                                             Heitjan, 2008                          NR                                                                                                              NR                                    NR                                     NR               3%                                 Initiation rates and successful quit attempts                                                     USA and ECA
                                             Hojgaard, 2011                         2                                                                                                               10 years and life‐time                Societal                               3.5%             3.5%                               Quit and relapse rates                                                                            ECA
                                             Hoogendoorn, 2008                      4 + 6                                                                                                           Life‐time                             Health‐care payer                      1.5%             4%                                 Abstinence rates                                                                                  USA and PSA
                                             Howard, 2008                           4 + 6                                                                                                           Life‐time                             Health‐care system                     3%               3%                                 Continuous abstinence rates                                                                       USA and PSA
                                             Igarashi, 2009                         Success‐alive, failure‐alive, sick‐smoke, sick‐non‐smoke, death                                                 Until age 90                          Health‐care payer                      3%               3%                                 Abstinence rates                                                                                  USA, MSA, and PSA
                                             Knight, 2010                           NR                                                                                                              Life‐time                             NR                                     3%               3%                                 Quit rates                                                                                        USA and PSA
                                             Lal, 2014                              3 + Mortality due to: cancer, COPD, CHD, stroke, other diseases                                                 Life‐time                             Health sector                          3%               5%                                 Quit rates                                                                                        PSA
                                             Levy, 2006                             NR                                                                                                              20 years                              Employer                               NR               5%                                 Probability of smoking cessation                                                                  DSA
                                             Linden, 2010                           4 + 6                                                                                                           Life‐time                             Societal                               5%               5%                                 Continuous abstinence rates                                                                       USA, MSA, and PSA
                                             Olsen, 2006                            3                                                                                                               Life‐time                             Payer                                  3.5%             3.5%                               Abstinence rates                                                                                  USA and PSA
                                             Pinget, 2007                           NR                                                                                                              1 year                                Third‐party payer                      NR               3%                                 Point abstinence at 1 year                                                                        USA
                                             Simpson, 2013                          Quit or continue smoking                                                                                        20 years                              NR                                     3%               3%                                 Rates for media awareness and quitline and (NYTCP) NRT utilization rates                          NR
                                             Taylor, 2011                           Recent quitter, smoker (lung CA, CHD, MI, stroke, COPD), former smoker (lung CA, CHD, MI, stroke, COPD), dead   Life‐time                             Health service (UK NHS)                3.5%             3.5%                               Abstinence rates                                                                                  USA
                                             Vemer, 2010a                           4                                                                                                               Life‐time                             Health‐care system                     0--5.0%          3.0--5.0%                          Change in incremental net monetary benefits                                                       NR
                                             Von Wartburg, 2014                     Exclusive health states as a function of their demographics and smoking status.                                 Life‐time                             Health‐care system and societal        NR               5%                                 Quit rates                                                                                        USA and PSA
                                             Welton, 2008                           NR                                                                                                              Life‐time                             Health service (UK NHS)                Not discounted   Not required                       Abstinence rates                                                                                  MSA and PSA
  Most reported                                                                     NR (*n* = 11), 4 (*n* = 3) and combined with 6 (*n* = 4)                                                        Life‐time (*n* = 21)                  Health‐care system/payer (*n* = 17)    3% (*n* = 12)    3% (*n* = 16)                      Quit/abstinence rates (*n* = 24)                                                                  USA with PSA (*n* = 9)
  Decision‐tree model (*n* = 9)              Boyd, 2009                             NR                                                                                                              4 or 52 weeks                         Health service (UK NHS)                NR               NR                                 Quit rates                                                                                        USA and MSA
                                             Levy, 2002                             Quit attempt or no quit attempt, quit or fail                                                                   1 year                                Health‐care payer                      NR               Not required                       Predicted quit rates                                                                              USA and MSA
                                             McGhan, 1996                           NR                                                                                                              NR                                    Employer                               NR               NR                                 Quit rates                                                                                        NR
                                             Nielsen, 2000                          NR                                                                                                              NR                                    Employer                               NR               3%                                 Quit rates                                                                                        USA
                                             Song, 2002                             NR                                                                                                              NR                                    Health service (UK NHS)                NR               Not required                       Quit rates                                                                                        ECA
                                             Tran, 2002                             NR                                                                                                              1 year                                Payer                                  3%               Not required                       Continuous abstinence rates                                                                       USA
                                             Halpern, 2007b                         Quit attempt or no quit attempt, quit or fail, resume                                                           2, 5, 10 or 20 years                  NR                                     NR               3%                                 Quit rates                                                                                        NR
                                             Jackson, 2007                          Quit or continue smoking                                                                                        1 year                                Employer                               NR               Not required                       Continuous abstinence rates                                                                       NR
                                             Xu, 2014                               Current smoker, quit attempt or continue smoking                                                                NR                                    Funding agency                         3%               3%                                 Quit rates                                                                                        USA
  Most reported                                                                     Quit attempt or no quit attempt, (quit or fail) (*n* = 4)                                                       Short‐term (*n* = 5)                  Health‐care system/payer (*n* = 4)     3% (*n* = 2)     3% (*n* = 3)                       Quit/abstinence rates (*n* = 9)                                                                   USA (*n* = 3) or in combination with MSA (*n* = 2)
  Remaining models reported (*n* = 25)                                                                                                                                                                                                                                                                                                                                                                                                 
  Markov & Monte Carlo                       Bauld, 2011                            Ex‐smoker, smoker, death and smoking‐related death                                                              1 year or life‐time                   Health service (UK NHS)                3.5%             NR                                 Continuous abstinence rates                                                                       DSA
  DES                                        Warner, 1996                           NR                                                                                                              50 years                              Societal and employer                  NR               3%, 3.5%, 4%                       Quit rates                                                                                        USA and ECA
                                             Xenakis, 2009                          NR                                                                                                              1 year                                Health‐care payer                      NR               Not required                       Continuous abstinence rates                                                                       USA
  CDM                                        Over, 2014                             1 + age, gender, SES                                                                                            75 years                              Health‐care system                     NR               1.5% and 4%                        Quit rates                                                                                        USA and MSA
                                             Van Baal, 2007                         1 + 14‐smoking related chronic diseases                                                                         100 years                             Health‐care system                     1.5%             4%                                 Price elasticity of tobacco consumption                                                           USA
                                             Vemer, 2010b                           NR                                                                                                              20 years and life‐time                Health‐care system                     1.5%             4%                                 Additional number of successful quitters                                                          NR
  TPM                                        Ahmad, 2005a                           1                                                                                                               50 years                              Societal                               3%               3%                                 Initiation rates                                                                                  NR
                                             Ahmad, 2005b                           1                                                                                                               50 years                              Societal                               3%               3%                                 Initiation rates                                                                                  USA
  QBM                                        Hurley, 2008                           NR                                                                                                              Life‐time                             NR                                     3%               3%                                 Reduction in smoking prevalence                                                                   DSA, MSA, and PSA
  WHO model                                  Lai, 2007                              NR                                                                                                              100 years                             Societal                               3%               3%                                 Change in disease incidence                                                                       ECA
  GHO                                        Bolin, 2006                            4                                                                                                               20 years                              Health‐care and societal               3%               3%                                 QALY                                                                                              USA, MSA, and PSA
  ACT                                        Stapleton, 1999                        NR                                                                                                              Life‐time                             Health service (UK NHS)                1.75%            Not required                       Additional number of LY saved                                                                     USA
  Decision analytical/simulation modelling   Brown, 2014                            NR                                                                                                              Until age 65                          NR                                     3.5%             NR                                 Increase in quit attempts                                                                         USA
                                             Cantor, 2015                           Short term: quit or no‐quit. Long term: alive or dead                                                           1 year or life‐time                   Health‐care provider                   3%               3%                                 Quit rates                                                                                        USA and MSA
                                             Croghan, 1997                          NR                                                                                                              Life‐time                             NR                                     0%, 3%, 5%       Not required                       Abstinence rates                                                                                  USA
                                             Halpern, 2007a                         Continued cessation, relapse, resume smoking, continued smoking                                                 10 years                              NR                                     NR               3%                                 Quit rates                                                                                        NR
                                             Hill, 2006                             NR                                                                                                              6 months                              Texas government                       NR               Not required                       \% individuals not smoking at 6 months                                                            USA and MSA
                                             Nohlert, 2013                          NR                                                                                                              Until age 85                          Societal                               3%               3%                                 Abstinence rates                                                                                  USA, MSA, and PSA
                                             Ong, 2005                              NR                                                                                                              1 year                                NR                                     3%               Not required                       Sustained quitters generated                                                                      MSA and PSA
                                             Shearer, 2006                          NR                                                                                                              NR                                    Government                             NR               Not required                       Continuous abstinence rates                                                                       MSA
                                             Stapleton, 2012                        NR                                                                                                              Life‐time                             Health service                         3.5%             1.5--3.5%                          Abstinence rates                                                                                  Various possible
  Dynamic/static modelling (*n* = 3)         Feenstra, 2005                         1                                                                                                               75 years                              Societal                               4%               4%                                 Abstinence rates                                                                                  USA and MSA
                                             Ranson, 2002                           NR                                                                                                              NR                                    NR                                     3.0--10.0%       3.0--10.0%                         Number of deaths averted                                                                          ECA
                                             Van Genugten, 2003                     Current or former smoker. Lung cancer, CHD, stroke, and COPD                                                    Period 1998--2050                     NR                                     NR               NR                                 Total number of life‐years lost as the sum of the remaining life expectancy at the age of death   MSA
  SmokingPaST Framework (*n* = 1)            O\'Donnell, 2011                       NR                                                                                                              NR                                    NR                                     NR               NR                                 Quit attempts                                                                                     NR
  Most reported                              Not reported (*n* = 15), 1 (*n* = 3)   Life‐time (*n* = 7)                                                                                             Health‐care system/payer (*n* = 10)   Not reported (*n* = 8), 3% (*n* = 8)   3% (*n* = 8)     Quit/abstinence rates (*n* = 13)   USA (*n* = 6) or combinations with USA (*n* = 7)                                                  

This refers to the states considered in the model and may include: (1) never smoker, current smoker, former smoker; (2) never smoker, current smoker, ex‐smoker, death; (3) current smoker, former smoker, death; (4) current smoker, recent quitter, long‐term quitter; (5) no morbidity, chronic obstructive pulmonary disease (COPD) or lung cancer, coronary heart disease (CHD) or stroke first event, CHD or stroke subsequent event, death from CHD/stroke, death from COPD/lung cancer, death (all cause); (6) no current morbidity, asthma exacerbation, CHD or stroke: post first event, COPD or lung cancer, CHD or stroke: post subsequent event, death (CHD or stroke), death (COPD or lung cancer), death (all cause).

Uncertainty analysis: USA = univariate sensitivity analysis; MSA = multivariate sensitivity analysis; ECA = extreme case analysis; PSA = probabilistic sensitivity analysis; DSA = deterministic sensitivity analysis; NRT = nicotine replacement therapy; NYTCP = New York Tobacco Control Program; SES = socio‐economic status; MI = minor limitations; SC = ; NR = not reported; QALY = quality adjusted life years.

Several (18 of 30) studies based on Markov models provided sufficient information on transition or health states used in the model. The most frequently used transition states were current smoker, former smoker or death, while health states included asthma exacerbation, coronary heart disease (CHD), stroke, chronic obstructive pulmonary disease (COPD) and lung cancer. In decision‐tree models (*n* = nine of 64) the most reported transition states were quit attempt or no quit attempt, often combined with success to quit or failure to quit.

The majority of the Markov models used a life‐time horizon (*n* = 22 of 30) while decision‐tree models considered a time between 1 and 50 years. Most of the studies based on other models lacked sufficient information, or reported a time‐horizon of 50 years. Most evaluations used a health‐care and/or payer perspective (*n* = 50 of 64). Twelve of 64 used a societal perspective. The reported primary measure of effectiveness in all models was quit rate or its variants (e.g. continuous abstinence rates).

The majority of the studies (*n* = 55 of 64) performed sensitivity analyses to account for uncertainties in their estimates. Markov model‐based studies performed mainly both univariate and probabilistic sensitivity analyses, decision‐tree models used univariate sensitivity analyses often in combination with multivariate sensitivity analyses (*n* = five of nine), and the other models (*n* = 25 of 64) conducted univariate sensitivity analyses (*n* = 13 of 25).

Quality assessment and transferability {#add13748-sec-0016}
--------------------------------------

Of the 64 included studies assessed for quality, 15 were excluded based on the first criteria (no health‐care perspective), 12 based on the second (no cost benefit or cost--utility analysis) and 24 on the final criteria (having major limitations). As shown in Table [3](#add13748-tbl-0003){ref-type="table-wrap"}, 13 of 64 studies were then classified as having minor limitations, 35 as having potentially serious limitations and 16 as having very serious limitations.

###### 

Results of the quality assessment.

  Classification                    Studies
  --------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Minor limitations                 Annemans, 2015; Annemans, 2009; Athanasakis, 2012; Bolin, 2006; Bolin, 2008; Bolin, 2009b; Boyd, 2009; Cornuz, 2003; Guerriero, 2013; Hoogendoorn, 2008; Howard, 2008; Over, 2014; Stapleton, 1999
  Potentially serious limitations   Ahmad, 2005a; Ahmad, 2005b; Bae, 2009; Bauld, 2011; Bolin, 2009a; Brown, 2014; Cantor, 2015; Chevreul, 2014; Cornuz, 2006; Feenstra, 2005; Fiscella, 1996; Halpern, 2007b; Heitjan, 2008; Hill, 2006; Hojgaard, 2011; Hurley, 2008; Igarashi, 2009; Linden, 2010; Levy, 2002; Nohlert, 2013; Ong, 2005; Pinget, 2007; Shearer, 2006; Simpson, 2013; Song, 2002; Stapleton, 2012; Taylor, 2011; Tran, 2002; Van Baal, 2007; Vemer, 2010a; Vemer, 2010b; Von Wartburg, 2014; Warner, 1996; Welton, 2008; Xenakis, 2009
  Very serious limitations          Bertram, 2007; Croghan, 1997; Dino, 2008; Halpern, 2007a; Knight, 2010; Lai, 2007; Lal, 2014; Levy, 2006; McGhan, 1996; Nielsen, 2000; Olsen, 2006; Ranson, 2002; Van Genugten, 2003; Xu, 2014; Jackson, 2007; O\'Donnell, 2011

Table [4](#add13748-tbl-0004){ref-type="table-wrap"} provides an overview of the scoring per question on the EURONHEED checklist for the 13 studies judged as having sufficient quality including the summary scores. The studies' total scores varied between 57 and 87% and the scores of the transferability checklist from 50 to 97%.

###### 

Results of the European Network of Health Economic Evaluation Databases (EURONHEED) checklist.

  1 = yes, 0.5 = partially, 0 = no/no information, NA = not Applicable   Annemans, (2015)   Annemans, (2009)   Athanasa‐kis, (2012)   Bolin, (2006)   Bolin, (2008)   Bolin, (2009b)   Boyd, (2008)   Cornuz, (2003)   Guerriero, (2013)   Hoogen‐doorn, (2008)   Howard, (2008)   Over, (2014)   Stapleton, (1999)
  ---------------------------------------------------------------------- ------------------ ------------------ ---------------------- --------------- --------------- ---------------- -------------- ---------------- ------------------- ---------------------- ---------------- -------------- -------------------
  Q1                                                                     1                  1                  1                      1               1               1                1              1                1                   1                      1                1              1
  Q2                                                                     0                  1                  1                      1               1               1                0              1                1                   1                      1                1              1
  **HT1**                                                                **0.5**            **0**              **0.5**                **0.5**         **1**           **0**            **1**          **1**            **1**               **1**                  **0.5**          **1**          **0.5**
  **HT2**                                                                **0.5**            **0**              **0.5**                **0.5**         **0.5**         **1**            **0**          **1**            **1**               **1**                  **0.5**          **1**          **0.5**
  SE1                                                                    0.5                0.5                1                      1               1               0                1              1                0.5                 0                      0                1              1
  **SE2**                                                                **0.5**            **1**              **1**                  **1**           **1**           **1**            **1**          **0.5**          **1**               **1**                  **1**            **1**          **1**
  **P1**                                                                 **1**              **1**              **1**                  **0.5**         **0.5**         **1**            **1**          **1**            **1**               **1**                  **1**            **1**          **1**
  **SP1**                                                                **1**              **1**              **1**                  **1**           **1**           **1**            **1**          **1**            **1**               **1**                  **1**            **0.5**        **1**
  SP2                                                                    0.5                0.5                0.5                    1               1               1                1              0                0.5                 1                      0.5              1              0
  **SP3**                                                                **0**              **0.5**            **0.5**                **NA**          **1**           **NA**           **0.5**        **NA**           **0**               **0.5**                **0.5**          **NA**         **0**
  SP4                                                                    0                  0                  0                      1               1               0.5              0              0.5              1                   0.5                    0.5              NA             0
  M1                                                                     0.5                0.5                0.5                    0.5             0.5             1                1              NA               1                   1                      1                NA             0.5
  M2                                                                     1                  1                  1                      1               1               1                1              1                1                   1                      1                0.5            NA
  E1                                                                     NA                 NA                 NA                     0.5             1               1                0              NA               0.5                 NA                     NA               NA             1
  E2                                                                     NA                 NA                 NA                     NA              1               1                0.5            NA               0.5                 NA                     NA               NA             1
  E3                                                                     0                  0                  0                      0               0               0                NA             0.5              NA                  0                      0                0              NA
  E4                                                                     NA                 NA                 NA                     NA              NA              NA               NA             NA               NA                  NA                     NA               NA             NA
  **E5**                                                                 **1**              **0.5**            **0.5**                **1**           **1**           **1**            **1**          **1**            **1**               **1**                  **1**            **1**          **1**
  E6                                                                     0                  0                  0                      0               0               0                0              0                0                   0                      0                0              1
  **E7**                                                                 **NA**             **NA**             **NA**                 **0.5**         **0.5**         **1**            **0**          **NA**           **1**               **1**                  **NA**           **0**          **0**
  B1                                                                     1                  1                  1                      1               1               1                1              1                1                   1                      1                1              1
  B2                                                                     0                  0                  0                      0.5             0.5             0                0              NA               0.5                 NA                     1                0              NA
  B3                                                                     1                  1                  1                      0.5             0.5             0                0              NA               0.5                 NA                     0                0              NA
  B4                                                                     0                  0                  0                      NA              NA              NA               NA             NA               NA                  NA                     0                0              NA
  **B5**                                                                 **1**              **0.5**            **1**                  **1**           **1**           **0**            **1**          **0**            **1**               **1**                  **1**            **0**          **0.5**
  **C1**                                                                 **1**              **0.5**            **0.5**                **1**           **1**           **1**            **1**          **0.5**          **0.5**             **1**                  **1**            **1**          **1**
  C2                                                                     0.5                0.5                0.5                    1               1               0.5              1              1                1                   1                      1                0              1
  C3                                                                     1                  1                  1                      1               0.5             0                1              1                0.5                 1                      1                0              1
  C4                                                                     1                  1                  0.5                    1               0.5             0                1              1                1                   1                      1                1              1
  **C5**                                                                 **0.5**            **0.5**            **1**                  **0.5**         **1**           **1**            **1**          **0.5**          **1**               **1**                  **1**            **1**          **1**
  **C6**                                                                 **0**              **0**              **0**                  **0.5**         **1**           **1**            **1**          **0.5**          **0.5**             **1**                  **1**            **0**          **1**
  **C7**                                                                 **1**              **1**              **1**                  **1**           **1**           **1**            **1**          **1**            **1**               **1**                  **1**            **1**          **1**
  C8                                                                     0.5                0.5                0.5                    0               1               1                1              1                1                   1                      1                1              1
  **C9**                                                                 **1**              **1**              **1**                  **1**           **1**           **1**            **1**          **1**            **1**               **1**                  **1**            **1**          **1**
  C10                                                                    NA                 NA                 NA                     NA              NA              0.5              NA             1                NA                  NA                     NA               NA             NA
  C11                                                                    1                  1                  1                      1               1               0                0              1                0.5                 1                      1                0              0
  D1                                                                     1                  1                  1                      1               1               1                1              1                1                   1                      1                1              1
  D2                                                                     1                  1                  1                      1               1               1                1              NA               1                   1                      1                1              NA
  D3                                                                     1                  1                  1                      1               1               1                0              1                1                   1                      1                1              0.5
  D4                                                                     1                  0                  05                     0.5             0.5             0.5              0              0                0                   0.5                    0.5              0              0
  **S1**                                                                 **0**              **0**              **0**                  **0**           **0**           **1**            **0.5**        **0.5**          **0**               **1**                  **1**            **0.5**        **0**
  **O1**                                                                 **0**              **0**              **0**                  **1**           **0**           **1**            **1**          **1**            **1**               **1**                  **1**            **0**          **0**
  Summary scores[a](#add13748-note-0006){ref-type="fn"} (%)                                                                                                                                                                                                                                       
  Total[b](#add13748-note-0007){ref-type="fn"}                           61                 57                 64                     74              79              67               70             77               76                  87                     78               59             69
  Transferability[c](#add13748-note-0008){ref-type="fn"}                 60                 50                 63                     73              81              80               88             75               81                  97                     90               67             66

Full items of the EURONHEED checklist are described in Supporting information, [Table S4](#add13748-supitem-0001){ref-type="supplementary-material"}. Items comprising the transferability subchecklist are shown in bold type.

Average of the total summary score: 71%; average of the transferability summary score: 75%.

Summary scores were calculated using the formula as in EURONHEED checklist: $\frac{1}{n - x}\sum_{i}\mathit{Si} \times 100$ *.*

Total summary score, number of questions = 42.

Transferability summary score, number of questions = 16.

The average score per section presented as the percentage of the total score are shown in Fig. [2](#add13748-fig-0002){ref-type="fig"}. The average score per section was 0.69 (range = 0.35--0.92). The sections that scored below the average (69%) were: health technology assessment study population, effectiveness, benefit measure, variability and generalizability.

![Percentage of total score per section. Calculated as the average of the% of total score of subitems. \[Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](ADD-112-946-g002){#add13748-fig-0002}

Discussion {#add13748-sec-0017}
==========

Key findings {#add13748-sec-0018}
------------

Markov‐based state transition models with QALY as the outcome measure were the most frequently used technique in evaluating the cost‐effectiveness of smoking cessation interventions. However, the majority of the studies were reported poorly, making it hard to assess their transferability using the existing checklist‐based method. Where such assessment was possible, studies showed a wide variation in transferability scores, driven mainly by the method of selecting populations, assessing effectiveness and outcomes and estimating variability and generalizability of their own findings.

Relative transferability {#add13748-sec-0019}
------------------------

The EURONHEED method assumes that without a quality score it would be impossible to transfer a study to another setting [9](#add13748-bib-0009){ref-type="ref"}, [32](#add13748-bib-0032){ref-type="ref"}, [95](#add13748-bib-0095){ref-type="ref"}. Therefore, the explicit assessment using this method resulted in some studies being more favourable candidates than others. However, on average, all studies lacked in some attributes for full transferability. One of the main differences between a high score and a low score is how differently the studies scored on the questions on costs. For example, Annemans *et al*. (2009), with a score of 0.50, addressed most of the cost questions only partially, whereas Hoogendoorn *et al*. (2008), with a score of 0.97, did so fully. Therefore, costs are important determinants of the transferability assessment [9](#add13748-bib-0009){ref-type="ref"}. Our review also highlighted other determinants; namely, selection of study population, intervention and comparator descriptions, effectiveness and benefit measures and variability/generalizability analyses---all scoring below the overall average score. Without a threshold, it was not possible to rank the assessed studies on their relative transferability, and this will be explored further below.

Comparison to current literature {#add13748-sec-0020}
--------------------------------

Several systematic reviews are available on the cost‐effectiveness of smoking cessation [22](#add13748-bib-0022){ref-type="ref"}, [23](#add13748-bib-0023){ref-type="ref"}, [24](#add13748-bib-0024){ref-type="ref"}, but only one systematic review looking at model‐based economic evaluations [20](#add13748-bib-0020){ref-type="ref"}. Most of the studies included in their review used the Markov model with long‐term time horizons, included comparable health states and reported the similar measures of effectiveness and outcomes as ours, and common weaknesses included poor reporting of the modelling details. However, a key difference from our review is that they did not build on their findings to evaluate the extent to which such models could be transferable from the original context to others, for wider benefits [9](#add13748-bib-0009){ref-type="ref"}, [10](#add13748-bib-0010){ref-type="ref"}, [17](#add13748-bib-0017){ref-type="ref"}. In areas outside smoking cessation, Korber has evaluated physical activity interventions for their transferability [96](#add13748-bib-0096){ref-type="ref"}. Consistent with our findings, she also found that a very few included studies explored variability from place to place and discussed caveats regarding the generalizability of results, 'leading to a wide variation in the transferability of the study results ranging from "low" to "very high" with everything in between' [96](#add13748-bib-0096){ref-type="ref"}. Another study [97](#add13748-bib-0097){ref-type="ref"} found that population and methodological characteristics were poorly reported---a finding that echoes our own results on the weaknesses of the models.

Implications of this review {#add13748-sec-0021}
---------------------------

Despite the availability of several guidelines on how to conduct and report adequately on economic evaluations [29](#add13748-bib-0029){ref-type="ref"}, [31](#add13748-bib-0031){ref-type="ref"}, there is still a considerable variation in the quality of published economic evaluations in smoking cessation. Arguably, this may limit the use of such evidence in other contexts. Some authors argue that the factors affecting the perception of applicability (the process question) and transferability (the outcome question) together might be broader than the factors associated with external validity [13](#add13748-bib-0013){ref-type="ref"}. Notwithstanding this difference, the EURONHEED method relies heavily upon the quality of reporting to ascertain transferability [32](#add13748-bib-0032){ref-type="ref"}. Therefore, such scores can be limited in use by the end‐users for two reasons. First, a poorly constructed model could have been reported well scoring high on the transferability scale and vice versa. Secondly, without a threshold score, it is hard to judge a study or to rank and compare across the studies. Nixon *et al*. [32](#add13748-bib-0032){ref-type="ref"} argue that the EURONHEED score should, rather, be used as a general guide in making decisions, but also note that the explicit assessment of transferability using this method will introduce an educational element, helping researchers to improve the design, conduct and reporting of future studies.

This review highlights the educational element noted above. Transparency in the model building and subsequent analysis and results, which can be captured by the quality of reporting, can enhance our understanding of the underlying process and outcome questions. However, a robust method would require more analyses based on the model outputs (as opposed to the checklists), backed up by the perceptions of actual stakeholders (including decision makers) as to what is relevant, adaptable, valid and transferable to them [13](#add13748-bib-0013){ref-type="ref"}, [16](#add13748-bib-0016){ref-type="ref"}. The European study on Quantifying Utility of Investment in Protection from Tobacco (EQUIPT) [98](#add13748-bib-0098){ref-type="ref"} provides some promise to that end by encompassing both model‐based analyses (e.g. on the parameter importance and variability) and the analysis of the stakeholder views (e.g. on the importance of interventions and intention to use economic evidence in policymaking) [99](#add13748-bib-0099){ref-type="ref"}, [100](#add13748-bib-0100){ref-type="ref"}, in addition to the systematic reviews based on the published models such as this. Although the final results of the EQUIPT study are yet to be published, this comprehensive framework appears to provide the end‐users with an understanding of a key transferability attribute---what changes in the economic model would make it transferable to their own settings and why [15](#add13748-bib-0015){ref-type="ref"}.

This review also reiterates the already identified challenge in terms of the way in which economic evaluations in broader public health are designed, conducted and reported [101](#add13748-bib-0101){ref-type="ref"}. The finding that only one‐fifth of the included study met quality classification for transferability implies that policymakers, researchers and journal editors need to work together in enhancing the quality of new economic evaluations and making it more transferable. The guidelines used by economic evaluation community and journals such as this are helpful to that end [102](#add13748-bib-0102){ref-type="ref"}. However, such guidelines should also emphasize the need for the authors to assess and report transferability of their models to the new contexts. This would ensure that future studies could consider adding model‐based analysis of transferability on to the checklist‐based evaluation, backed up by, where possible, analysis of the views of stakeholders.

Limitations {#add13748-sec-0022}
-----------

A major limitation of this review has been the limitation embedded in the existing method of transferability assessment [9](#add13748-bib-0009){ref-type="ref"}, [32](#add13748-bib-0032){ref-type="ref"}. Future research may overcome this limitation by adopting a comprehensive assessment as discussed above. In addition, limiting the search to English language only might have excluded some studies. However, we identified more model‐based economic evaluations than a previous similar review [22](#add13748-bib-0022){ref-type="ref"}. The use of three quality criteria [31](#add13748-bib-0031){ref-type="ref"} for inclusion of studies in the transferability assessment could potentially have introduced some bias, as it was based on the overall assessment, as opposed to some standard checklists such as those by Drummond [103](#add13748-bib-0103){ref-type="ref"} or Philips [104](#add13748-bib-0104){ref-type="ref"}. However, the variety of items included in our data extraction form as outlined in the best practice guidelines [102](#add13748-bib-0102){ref-type="ref"} were very similar to the Drummond or Philips checklists, implying the possibility of such bias to be minimal. Finally, exclusion of low‐/middle‐income countries to reduce study heterogeneity could have limited this review in its primary focus (i.e. evidence transferability to less‐affluent countries).

Conclusion {#add13748-sec-0023}
==========

Existing economic evaluations in smoking cessation vary in quality, resulting mainly from the way in which they selected their populations, measured costs and effects and assessed the variability and generalizability of their own findings. All studies lacked one or more key study attributes for full transferability. A robust design, coupled with comprehensive reporting of key study attributes, could make economic evaluations transferable to a new context.
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